Compare · NVO vs RFL
NVO vs RFL
Side-by-side comparison of Novo Nordisk A/S (NVO) and Rafael Holdings Inc. (RFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RFL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $184.33B, about 3316.3x RFL ($55.6M).
- Both names hit the wire about 7 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for RFL).
- Company
- Novo Nordisk A/S
- Rafael Holdings Inc.
- Price
- -
- -
- Market cap
- $184.33B
- $55.6M
- 1M return
- +6.11%
- -
- 1Y return
- -14.12%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 7
- 7
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Rafael Holdings Inc.
Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Latest NVO
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RFL
- Rafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- SEC Form 10-K filed by Rafael Holdings Inc.
- SEC Form 8-K filed by Rafael Holdings Inc.
- Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
- Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
- SEC Form 4 filed by Rafael Holdings Inc.
- Rafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
- Chief Financial Officer Polinsky David covered exercise/tax liability with 2,027 units of Class B Common Stock, decreasing direct ownership by 0.68% to 297,084 units (SEC Form 4)